While allogeneic HSCT is generally recognized as the best therapeutic option in NPM1-mutated AML patients showing FLT3-ITD, at least in cases with a high allelic ratio; conversely, this procedure in first CR is generally not recommended in patients harboring NPM1 gene mutations without FLT3-ITD [8,53,54]. Here, FLT3 is linked to acute myeloid leukemia.